转移性去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA-617放射配体治疗时初始影像与PSA变化的预后价值:ProsTIC登记分析
该研究基于ProsTIC登记(NCT04769817),纳入195例中103例在首周期后28天内PSA上升或稳定的转移性去势抵抗性前列腺癌患者,评估继续第二周期[177Lu]Lu-PSMA-617的获益。结果显示44%患者在C1后140天内达PSA-50,基线PSMA PET SUVmean≥10者PSA-50率更高(59% vs 37%),[18F]FDG代谢肿瘤体积与总生存相关,提示不应仅凭1周期后PSA反应停药。
要点
- 首周期后PSA上升或稳定者继续治疗仍有44%达PSA-50,不应仅凭早期PSA反应停药
- 基线PSMA PET SUVmean≥10者PSA-50率更高(59% vs 37%,OR 2.53,95%CI 1.08-5.95)
- [18F]FDG代谢肿瘤体积是与总生存唯一有意义的关联变量,可用于预后评估
核心结论
- 仅根据1周期后PSA反应决定停用[177Lu]Lu-PSMA-617并不明智,因为相当比例患者仍可达PSA-50或疼痛减轻。
- 基线影像参数具有预后价值,可辅助患者咨询与临床决策。
研究设计与样本
- 分析参与[177Lu]Lu-PSMA-617登记(ProsTIC registry,NCT04769817)的转移性去势抵抗性前列腺癌患者。
- 纳入首周期开始后28天内PSA上升(较基线≥25%升高)或稳定(较基线下降30%至升高25%)并接受第二周期治疗者。
- 195例中103例符合纳入标准(2021年1月5日至2023年3月30日),早期PSA上升31例(30%),稳定72例(70%)。
主要发现
- 103例中45例(44%)在C1后140天内达PSA-50。
- 早期PSA上升者31例中7例(23%)、稳定者72例中38例(53%)在C1后140天内达PSA-50。
- PSMA SUVmean≥10 vs <10者PSA-50率分别为59% vs 37%(OR 2.53,95%CI 1.08-5.95)。
- 共记录59例死亡,第二周期后中位总生存11.3个月。
- [18F]FDG代谢肿瘤体积是唯一与总生存有有意义关联的变量。
关键数值与推荐
- 生化反应定义为C1后20周内PSA较基线下降>50%(PSA-50)。
- 基线EORTC QLQ-C30疼痛评分≥10或BPI-SF≥2者中,分别有39/55例(71%)和17/37例(46%)达到临床有意义的疼痛减轻。
临床怎么用
- 不应仅因首周期后PSA未下降或上升而停用[177Lu]Lu-PSMA-617,应综合评估后继续治疗。
- 基线PSMA PET SUVmean和[18F]FDG代谢肿瘤体积可用于预后分层与患者咨询。
局限性
- 本研究为登记分析,非随机对照试验。
- 样本量有限(103例纳入分析)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
[177Lu]Lu-PSMA-617 radiopharmaceutical therapy improves survival and quality of life in patients with metastatic castration-resistant prostate cancer. We assessed whether patients who did not achieve an early prostate-specific antigen (PSA) decline after the first cycle (C1) benefited from further [177Lu]Lu-PSMA-617. Methods: We analyzed patients with metastatic castration-resistant prostate cancer participating in a registry of [177Lu]Lu-PSMA-617 (ProsTIC registry, NCT04769817). Patients with a PSA either rising (≥25% increase from baseline) or stable (30% decrease to 25% increase from baseline) within 28 d of starting treatment (C1) and consequently received a second dose (cycle 2) were included. Biochemical response was defined as a PSA decline of more than 50% from baseline (PSA-50) within 20 wk after C1. Quality of life was assessed on 2 validated scales. We evaluated the effect of PSA change and 3 imaging parameters (pretreatment PSMA PET SUVmean, pretreatment [18F]FDG PET metabolic tumor volume, and mean total tumor dosimetry on SPECT/CT after C1) with these outcomes and survival time after cycle 2. Results: Of 195 patients, 103 met inclusion criteria between January 5, 2021, and March 30, 2023, with an early PSA rise in 31 patients (30%) or stable PSA in 72 patients (70%). Of 103 patients, 45 (44%) achieved PSA-50 by 140 d after C1. Seven of 31 patients (23%) and 38 of 72 patients (53%) with early rising and stable PSA, respectively, had achieved a PSA-50 by 140 d after C1. A PSMA SUVmean of 10 or more versus an SUVmean of less than 10 conferred a higher chance of PSA-50 (59% vs. 37%; odds ratio, 2.53; 95% CI, 1.08-5.95). In total, 59 deaths were recorded with a median overall survival of 11.3 mo after cycle 2. [18F]FDG metabolic tumor volume was the only variable to have a meaningful association with overall survival. Patients with baseline pain scores of 10 or greater according to EORTC QLQ-C30 pain or 2 or greater according to BPI-SF had clinically meaningful reductions in pain in 39 of 55 patients (71%) and 17 of 37 patients (46%), respectively. Conclusion: Discontinuing [177Lu]Lu-PSMA-617 based solely on PSA response after just 1 cycle is not advisable as a substantial number of patients achieve PSA-50 or a reduction in pain. Baseline imaging parameters have prognostic utility and can assist in patient counseling and clinical decision-making.
引用
- Chen DC, Buteau JP, Papa N, et al. Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis. J Nucl Med. 2025. PMID: 41067860. doi:10.2967/jnumed.125.270804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。